SRR1797280
— · cohortSC
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSC
- subtype
- cohortSC
- age_years
- 56
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.470
- E2F_TARGETS+0.440
- G2M_CHECKPOINT+0.410
- MITOTIC_SPINDLE+0.370
- PROTEIN_SECRETION+0.370
- PANCREAS_BETA_CELLS+0.360
- UNFOLDED_PROTEIN_RESPONSE+0.260
- SPERMATOGENESIS+0.250
- DNA_REPAIR+0.230
- OXIDATIVE_PHOSPHORYLATION+0.230
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.420
- TNFA_SIGNALING_VIA_NFKB-0.420
- ALLOGRAFT_REJECTION-0.410
- IL6_JAK_STAT3_SIGNALING-0.410
- INFLAMMATORY_RESPONSE-0.410
- INTERFERON_ALPHA_RESPONSE-0.400
- MYOGENESIS-0.380
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.350
- IL2_STAT5_SIGNALING-0.330
- KRAS_SIGNALING_DN-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1797245 | — | cohortSC | 0.933 |
| 2 | BS_EFE4YEK3 | Med | Medulloblastoma | 0.928 |
| 3 | BS_HKZENFDA | medulloblastoma | — | 0.926 |
| 4 | SRR1797279 | — | cohortSC | 0.925 |
| 5 | SRR1797285 | — | cohortSC | 0.922 |
| 6 | TCGA-86-8054-01A-11R-2241-07 | — | cohortA3 | 0.919 |
| 7 | BS_1HQ76V6D | Embryonal tumors | — | 0.919 |
| 8 | SRR1797277 | — | cohortSC | 0.916 |
| 9 | BS_8QB4S4VA | Embryonal tumors | — | 0.916 |
| 10 | SRR13780268 | — | cohortSC | 0.913 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.470 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.370 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.360 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.260 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.230 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.170 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.110 | Idelalisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |